Swainsonine (Synthetic)
Share product
- structure.search.product.name Swainsonine (Synthetic)
- Numer katalogowy produktu: TRC-S885000
- Numer CAS: 72741-87-8
- Marka: TRC
Product Overview
Kod produktu
TRC-S885000
Numer CAS
Postać produktu
Neat
Wzór cząsteczkowy
C8 H15 N O3
Masa cząsteczkowa
173.21
Kategorie produktów
Alkaloids, TRC, Enzyme inhibitors, Additional Cancer Bioactive Molecules, Additional Neuro Products
Rodzaj produktu
Bioactive Small MoleculePurity
>95% (HPLC)
Dokumentacja
Szukasz innej serii?
Aby natychmiast wyświetlić wszystkie świadectwa analizy, zaloguj się na swoje konto
lub
Wyślij e-mailem łącze do pobrania
{{ errors[0] }}
{{ errors[0] }}
Więcej informacji dotyczących przetwarzania danych znajduje się w naszej Polityce prywatności.
Wpisz swój adres e-mail, a wyślemy Ci odpowiedni CoA dla partii:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}
{{ errors[0] }}
Wyślemy CoA na Twój adres e-mail {{ coaEmailPopupData.userEmail }}
Your request has been sent to our sales team to process.
Znajdź kartę charakterystyki dla swojego kraju
{{ errors[0] }}
{{ errors[0] }}
Więcej informacji dotyczących przetwarzania danych znajduje się w naszej Polityce prywatności.
Your request has been sent to our sales team to process.
Informacje o produkcie
Chemical Data
Nazwa analitu
Swainsonine
Numer CAS
72741-87-8
Wzór cząsteczkowy
C8 H15 N O3
Masa cząsteczkowa
173.21
Dokładna masa
173.1052
SMILES
O[C@@H]1CCCN2C[C@@H](O)[C@@H](O)[C@@H]12
InChI
InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1
IUPAC
(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol
Dane produktu
Temperatura przechowywania
-20°C
Temperatura podczas transportu
Room Temperature
Kraj pochodzenia
CANADA
Rodzaj produktu
Bioactive Small Molecule
Postać produktu
Neat
Purity
>95% (HPLC)
Product Description
Swainsonine is a plant alkaloid derived from Swainsona canescens (a leguminous plant). It is a reversible, active-site directed inhibitor of a-mannosidase at concentrations of 5-10mM. At acid pH, swainsonine resembles an intermediate in the hydrolysis of mannosidases.Swainsonine completely inhibits mammalian Golgi a-mannosidase II (a-3/6-mannosidase in the glycoprotein processing pathway) and mammalian lysosomal a-mannosidase (acid mannosidase). At higher concentrations, swainsonine also inhibits mammalian cytosolic a-mannosidase. It has been shown to inhibit growth of transformed fibroblasts in soft agar and to enhance the antiproliferative effects of INF on murine lymphoreticular tumor cells in vitro. It also blocks the expression of b1-6 branched complex-type oligosaccharides and shunts the pathway towards hybrid-type oligosaccharides. Swainsonine does not appear to inhibit secretion or expression of glycoproteins at the cell surface. Swainsonine is stable for at least 24 h at 37oC in culture media at physiological pH. Working concentration range is 17-1700 ng/ml (0.1-10mM). Swainsonine (at 1 mg/ml) is not cytotoxic and does not inhibit the growth of a variety of mammalian cell lines. Concentrations required to inhibit Golgi a-mannosidase II in vivo may be somewhat higher, as swainsonine tends to concentrate in the acid environment of cell lysosomes, where it exists as a charged cation and does not permeate through membranes readily.Swainsonine blocks the processing of high-mannose oligosaccharides to complex oligosaccharides. Glycoproteins synthesized in the presence of swainsonine tend to carry mostly high-mannose and hybrid oligosaccharide chains. With short treatments (<24 h) with the inhibitor, cells may retain some complex glycoproteins due to asynchronous cell growth and glycoprotein synthesis.
References: J. Biol. Chem., 258, 7578-7585 (1983), Methods Enzymol., 98, 135 (1983), EMBO Journal, 3, 551-556 (1984), Mol. Cell. Biol., 5, 3467-3475 (1985), Int. J. Cancer, 44, 685 (1989),Melanoma Res., 1, 43 (1991), Bonay, P., & Fresno, M.: Glycobiology, 9(5), 423-433 (1999), Klein, J-LD, et al.: Br. J. of Cancer, 80(1/2), 87-95 (1999)
{{ errors[0] }}